Table S1 Sample Clauses

Table S1. UV-Vis spectra of 1-8 in methanol and acetonitrile (λ in nm, ε in M-1cm-1). S λmax, MeOH εmax# ε254# λmax, ACN εmax# ε254# 1 H 225.9 2.56*104 4.21*103 229.1 2.02*104 9.10*103 2 CH3 244.9 2.61*104 2.12*104 250.0 1.74*104 1.68*104 3 OCH2CH3 247.0 1.82*104 1.56*104 251.1 1.55*104 1.52*104 4 CF3 226.0 1.75*104 1.76*103 226.0 2.14*104 8.52*103 5 C(O)OCH3 236.0 1.83*104 6.68*103 238.0 2.60*104 6.68*103 6 CN 236.9 3.17*104 9.61*103 239.0 2.93*104 1.54*104 7 C(O)CH3 244.0 3.36*104 2.35*104 244.0 0.27*104 2.09*104 8 N(Me)2 304.0 2.03*104 1.37*104 311.1 1.70*103 1.95*104 # εmax is absorption coefficient at maximum absorption, ε 254 is absorption coefficient at λ = 254 nm.
Sample 1
AutoNDA by SimpleDocs
Table S1. The Bowdle scales8
Sample 1
Table S1. Analytical (AEF) and surface (SEF) enhancement factors estimated at an R6G analyte concentration of 10-6 M and an excitation wavelength of 632.8 nm. REFERENCES for MATERIALS AND METHODS
Sample 1
Table S1. Residues showing significant differences in 1H and 15N chemical shifts ($Dav>0.3) between V44M IGF-I and IGF-I plus F1 peptide (8), where $Dav=($DNH2 + 0.17$D 2)1/2 (66). Chemical shifts for these residues in long-[Arg3] IGF-I (10) and long-[Leu60] IGF-I (11) are also included. The residues implicated in F1 peptide binding actions (8) are shown in black and others shaded in gray. residue V44M IGF-I IGF-I plus F1 Long-[Arg3]IGF-I Long-[Leu60] IGF-I NH N NH N NH N NH N Cys 6 8.25 120.2 8.47 118.0 8.38 119.7 8.33 118.3 Gly7* ------- ------- 8.86 109.7 7.74 110.0 7.63 108.3# Ala8* 8.49 126.5 8.77 128.5 8.98 130.3 8.83 128.2 Glu9 7.61 114.5 7.80 115.5 8.00 118.1 7.94 115.1# Leu10* ------- ------- 6.74 119.9 6.88 121.7 6.87 120.3 Val11 7.59 115.7 7.18 118.1 7.29 119.3 7.38 117.9 Phe16 7.71 119.0 8.29 121.2 7.84 120.6 7.38 117.9# Phe25 7.93 117.3 8.53 116.9 8.48 119.6 7.86 120.3# Ile43 7.91 120.4 7.58 121.5 7.89 122.4 7.74 121.4 Phe49 7.45 115.9 7.70 116.1 7.72 117.3 7.89 113.7# Arg50 7.93 116.5 7.42 117.1 7.53 119.9 7.95 119.4 Ser51 7.90 112.9 7.75 110.7 7.83 113.3 7.81 112.9 Leu54 7.73 122.6 8.67 127.0 7.59 123.6 7.57 122.5# Arg55 7.80 118.0 8.22 117.5 7.86 119.9 7.92 119.4 Glu58* ------- ------- 7.40 112.5 8.09 114.8 8.15 113.7 Tyr60 7.76 115.8 7.81 117.5 7.98 117.0 7.76 117.9 Cys61* ------- ------- 7.09 7.26 116.9 7.22 115.3 * Gly7, Leu10, Glu58 and Cys61 are not found in any spectra of 15˚C, 20˚C and 37˚C in V44M IGF-I. + Ala8 has a very weak peak in 2D HSQC. # Chemical shifts show significant differences among the three published IGF-I data sets. Table S2. XXX intensities observed in Val44Met IGF-I compared with inter-proton distances for the mutated residue 44 in A) long-[Arg3] IGF-I (12) and B) IGF-I plus F1 peptide (8). Relative intensities (RI), calculated using the integrated intensity divided by the average noise in the 3D NOESY-HSQC spectrum, are designated S (strong, RI>3.5), M (medium, 3.5>RI>2.0) and W (weak, RI<2.0). HN-HN and HN-HA NOEs and corresponding distances are shaded in grey. Note that the relative strengths of the sequential NOEs to Met44 HN correspond more closely with the distances in the long-[Arg3] IGF-I structure. Several backbone-to-backbone NOEs expected from the long-[Arg3] IGF-I structure are not seen in spectra of Val44Met IGF-I as follows: HN of Asn26, Gly42, Glu46, Cys47, Cys48 to Met44 HN; HN of Leu10, Val11, Glu46, Cys47, Cys48 to Met44 HA. NOEs expected from the IGF-I+F1 structure but not seen in spectra of Val44Met IGF-I a...
Sample 1
Table S1. The Primers Used for qRT-PCR‌ Name* Forward (5’-3’) Reverse (5’-3’) hALKBH5 ATCCTCAGGAAGACAAGATTAG TTCTCTTCCTTGTCCATCTC hCAV1 CGACCCTAAACACCTCCACGA TAAATGCCCCAGATGAGTGC hCCNB1 AATAAGGCGAAGATCAACATGGC TTTGTTACCAATGTCCCCAAGAG hCDK1 AAACTACAGGTCAAGTGGTAGCC TCCTGCATAAGCACATCCTGA hEGR1 CTCTCCAGCCTGCTCGTC AGCAGCATCATCTCCTCCAG hFOXO4 GCCTCGTTGTGAACCTTGATG ACTGACACTTGCCCAGATTTACG hGAPDH CCCACTGCCAACGTGTCA AAGTCAGAGGAGACCACCT rALKBH5 TTCGGCTGCAAGTTCCAGTT CAGCAGCATATCCACTGAGCA rBCL2 CGGGATGGGGTAAACTGG AGGTGGTCATTCGTGG rCASP9 GGTGGGGAGCAGAAAGACC AGCTGGTCGAAGGTCCTCAA rGAPDH GAAGGTGAAGGTCGGAGT CATTGACAACAATATCC rNANOG CCTATGCCTGTGATTTGTGGG AGGTTGTTTGCCTTTGGGAC rOCT4 GGAATGAGGGACAGGGGGAG ACTCCCCTGCCCCCACCCT rC-KIT ACACGTGCACCAACAAACAC CAAGGAGCGGTCAACAAGGA rGFRA1 GGGAGAAGCCCAACTGTTTG GACAGCTGCTGACAGACCTTGA rNANOS3 CCTGCACAGGTTTCAGAGGT TGGGAGTGGTCCTCATAGGG rPIWIL1 ATAACTGGCCAGGTGTCATTCGT AGGTAGTAAAGGCGGTTTGACA rPLZF AGCGGTTCCTGGATAGTTTGC TTCGAAAACTGTGCACCACACT rTNP1 AATTACCGCTCCCACTTGTGA TGATCCACATTCCATAGGCTCC rTNP2 GAGCTCAGGACGGAAATCCAA CCTGCAAGAAGATTGACTTCG rTOP2B GCACTGACCTGGGTGAACAA CCCACATGAACTGCGTCAAT rVASA GAAGCTGATCGCATGTTGGATA TGCAGCCAACCTTTGAATTTC CASP3 TCGCTTTGTGCCATGCTGAAAC TGTTGCCACCTTTCGGTTAACC SOX2 GCCGAGTGGAAACTTTTGTCG GGCAGCGTGTACTTATCCTTCT
Sample 1

Related to Table S1

  • Table 3 .2: Worked out example of calculating the monitoring quality score of a population for population trend Attribute Country Importance Quality (qij) Weight (wij) wij × qij T MA 2 1 30.0 30.0 T MR 3 2 75.0 150.0 T SN 1 2 2.5 5.0 T GW 1 3 2.5 7.5 T GN 1 3 2.5 7.5 T SL 1 3 2.5 7.5 Sums: 115.0 207.5 Weighted mean rounded to the nearest integer: 2.0

  • Table 2 Software Subscription Use Case OpenShift Enterprise OpenShift Enterprise Broker Infrastructure OpenShift Enterprise is intended to be used as a platform as a service and will be supported only when used in that capacity. OpenShift Enterprise is not supported on non-server hardware such as desktops or workstations. OpenShift Enterprise is intended for use on a dedicated Physical Node or Virtual Guest; running other applications and/or programs of any type on the Physical Node or Virtual Guest can have a negative impact on the function and/or performance. Red Hat JBoss Enterprise Application Platform for OpenShift and/or Red Hat JBoss EAP for xPaaS will be supported in accordance with the terms of Exhibit 1.B.

  • Table 4 Ending this Addendum when the Approved Addendum Changes Which Parties may end this Addendum as set out in Section 19: Importer Exporter Ending this Addendum when the Approved Addendum changes Part 2: Mandatory Clauses Entering into this Addendum

  • Table 2 (definition of “Casino Gross Revenue”) 15(e) 2 (definition of “Commissioning”) 19 2 (definition of “Committee’s Nominated Representative) 20(1) 6(1)(c) 20(2) 7(8)(a) 21(d) 11(1) 21(e) 11(2) 22(2) 11(3) 23(b) 14(d) 33(2) 15(a)(B) 35(1) 15(b)(i) 35(2) 15(c) 36(b) 15(d) 36(c)

  • Table 1 4 If ‘Yes’ to any then you are likely required to carry out a DPIA under Article 35 GDPR. If ‘No’, to all then a DPIA may not be required. 1 xxxxx://xxx-xxx.xxxxxx.xx/legal-content/EN/TXT/?uri=CELEX:02016R0679-20160504

  • Captions; Table of Contents The captions or headings in this Agreement and the Table of Contents are for convenience only and in no way define, limit or describe the scope and intent of any provisions of this Agreement.

  • CROSS-REFERENCE TABLE Trust Indenture Act Section Indenture Section 310 (a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A.

  • Definitions and Basic Provisions The following definitions and basic provisions shall be used in conjunction with and limited by the reference thereto in the provisions of this lease:

  • Headings; Table of Contents The headings of the sections of this Agreement and the table of contents have been inserted for convenience of reference only and shall not be deemed a part of this Agreement.

  • REFERENCE TABLE TIA Section Indenture Section ----------- ----------------- 310(a)(1)..................................................... 6.10 (a)(2)..................................................... 6.10 (a)(3)..................................................... N.A. (a)(4)..................................................... N.A. (a)(5)..................................................... 6.08 (b)........................................................ 6.08; 6.10 (c)........................................................ N.A. 311(a)........................................................ 6.11 (b)........................................................ 6.11 (c)........................................................ N.A. 312(a)........................................................ 2.05 (b)........................................................ 10.03 (c)........................................................ 10.03 313(a)........................................................ 6.06 (b)(1)..................................................... N.A. (b)(2)..................................................... 6.06 (c)........................................................ 6.06; 10.02 (d)........................................................ 6.06 314(a)........................................................ 3.02; 3.03; 10.02 (b)........................................................ N.A. (c)(1)..................................................... 10.04 (c)(2)..................................................... 10.04 (c)(3)..................................................... N.A. (d)........................................................ N.A. (e)........................................................ 10.05 (f)........................................................ N.A. 315(a)........................................................ 6.01(b) (b)........................................................ 6.05; 10.02 (c)........................................................ 6.01(a) (d)........................................................ 6.01(c) (e)........................................................ 5.11 316(a)(last sentence)......................................... 10.06 (a)(1)(A).................................................. 5.05 (a)(1)(B).................................................. 5.02; 5.04; 8.02 (a)(2)..................................................... N.A. (b)........................................................ 5.07 317(a)(1)..................................................... 5.08 (a)(2)..................................................... 5.09 (b)........................................................ 2.04 318(a)........................................................ 10.01 --------------------------

Time is Money Join Law Insider Premium to draft better contracts faster.